Cannabis Science Delegation Arrives in South Africa to Launch a Historic Africa Healthcare Initiative Led by President & CEO, Co-Founder, Mr. Raymond C. Dabney
CAPE TOWN, SOUTH AFRICA--(Marketwired - May 23, 2016) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, announces arrival of a Cannabis Science delegation beginning in Cape Town, South Africa to launch a historic Africa Healthcare initiative led by President & CEO, Co-Founder Raymond C. Dabney.
Mr. Dabney is accompanied by Dr. Allen A. Herman, the Chief Medical Officer (CMO) of CBIS, Mr. Melvin P. Foote, President and Executive Director of Constituency for Africa (CFA), and Dr. Julius Garvey, surgeon and noted advocate for African healthcare and a member of the Scientific Advisory Board (SAB) of CBIS.
Beginning in Cape Town, South Africa, the CBIS delegation is here to meet with key stakeholders in government, the private sector, civil society, and academia. The delegation will then move forward to other countries and major cities in the continent. CBIS is dedicated to collaboration with international regulatory agencies in South Africa and other African countries to provide access to high quality, first-class cannabinoid pharmaceuticals to those critically in need of new treatments for life threatening and debilitating conditions.
CBIS products, broadly described, are medical cannabinoid formulations developed from one or more of the cannabinoid compounds found in the cannabis plant. By establishing operations in Southern Africa to develop and supply pharmaceuticals throughout the African continent, CBIS intends to access an underserved market with a total population of over 1.1 billion people. Through Public Private Partnerships in Southern Africa, the Company believes it can bring new products to market and increase company revenues, all while contributing to economic development in Africa through job creation, capacity building, and technology transfer.
The Government and the educational and research leaders of South Africa continues its leadership in its development and implementation of initiatives to strengthen the country's health-care infrastructure and improve the delivery of health-care education and services to the South African people. Given this, we believe that South Africa and other African countries have indicated interest and are perceived to be ideal potential partners for CBIS as we explore opportunities to establish educational and pharmaceutical development operations in Sub-Saharan Africa.
The delegation will also discuss the critical role that the Raymond C. Dabney University (RCDU) will play in the development of cannabinoid and other plant-based pharmaceuticals across the continent. RCDU is developing partnerships with universities in the United States and these partnerships will expand education and training opportunities in law and healthcare to members of disadvantaged communities and populations, and provide intellectual and laboratory resources for pharmaceutical development. The delegation will discuss the expansion of this model partnership to include African governments across the continent including educational and research institutions.
The company believes that at the heart of its drug development program there is a broader development objective that will improve the capacities of government, educational and research partners in across the continent of Africa.
The discussions will explore three main areas:
1. The legislative and regulatory environment that governs the growth of cannabis and the development of approved medicines based on the cannabis plant. We will meet with and discuss this with government ministers of health and agriculture. Additionally, we will explore the processes required by the Medicines Control Councils (the FDA equivalent agencies) of African countries to establish drug development programs.
2. What partnerships with educational, research, and community organizations will be necessary for effective drug development programs?
3. What are the education and training needs of our potential African country partners?
"I am very excited to arrive on the African continent for my very first visit," said Mr. Dabney, "and I look forward to developing sustainable partnerships with the governments and people of Africa."
Mr. Melvin P. Foote, President and Executive Director of Constituency for Africa (CFA), said, "At the heart of this visit is the creation of a drug development program that emphasizes local job creation, education and training. The Constituency for Africa joins CBIS in this venture because we believe that this program will develop sustainable job creation across a number of key sectors."
Dr. Allen A. Herman, the Chief Medical Officer (CMO) of CBIS, suggested, "Drug development programs, by their very nature, require well-trained sophisticated personnel and that this comprehensive CBIS program will create the intellectual and industrial infrastructure that will serve as a platform for plant-based pharmaceutical development across a wide range of local sources."
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.